سعر اوبديفو 40مجم/4مل فيال وريدي 2026

Opdivo (nivolumab) 40 mg/4 ml (10 mg/ml) concentrate for intravenous infusion, single-dose vial; PD-1 blocking antibody.

• Unresectable or metastatic melanoma (alone or with ipilimumab); adjuvant treatment of completely resected stage IIB-IV melanomaDailyMed (U.S. NLM)
• Non-small cell lung cancer (several settings, including neoadjuvant with platinum-doublet chemotherapy)DailyMed (U.S. NLM)

• None (per US label).International label, same product · DailyMed (U.S. NLM)

• Immune-mediated adverse reactions, possibly severe or fatal, in any organ (pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic reactions, nephritis); withhold or permanently discontinue by severity.International label, same product · DailyMed (U.S. NLM)
• Infusion-related reactions: interrupt or slow infusion for grade 1-2; permanently discontinue for grade 3-4.International label, same product · DailyMed (U.S. NLM)

• Can cause fetal harm (animal data: increased abortion and premature infant death); verify pregnancy status; females of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.International label, same product · DailyMed (U.S. NLM)
• Do not breastfeed during treatment and for 5 months after the last dose.International label, same product · DailyMed (U.S. NLM)

• Nivolumab: Binds PD-1 and blocks its interaction with PD-L1/PD-L2, releasing PD-1 pathway-mediated inhibition of the anti-tumour immune response.